{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dasatinib+in+combination+with+imatinib", "query": { "intervention": "Dasatinib in combination with imatinib" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 9, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-02T17:35:32.460Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06124157", "title": "A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "B Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Blinatumomab", "type": "BIOLOGICAL" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Calaspargase Pegol", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Daunorubicin", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Imatinib", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Mercaptopurine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Pegaspargase", "type": "DRUG" }, { "name": "Prednisolone", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Thioguanine", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "366 Days", "maximum_age": "46 Years", "sex": "ALL", "summary": "366 Days to 46 Years" }, "enrollment_count": 222, "start_date": "2025-05-30", "completion_date": "2030-12-01", "has_results": false, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-10-02T17:35:32.460Z", "location_count": 143, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 121 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Downey", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06124157" }, { "nct_id": "NCT03610971", "title": "Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Phase Chronic Myeloid Leukemia", "Chronic Myeloid Leukemia, Chronic Phase" ], "interventions": [ { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "BCR-ABL Tyrosine Kinase Inhibitor (TKI)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2019-11-19", "completion_date": "2026-10", "has_results": false, "last_update_posted_date": "2026-04-02", "last_synced_at": "2026-10-02T17:35:32.460Z", "location_count": 8, "location_summary": "Tampa, Florida • Atlanta, Georgia • Montvale, New Jersey + 5 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Buffalo", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03610971" }, { "nct_id": "NCT00324077", "title": "Phase I Study of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic Phase", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Myeloid Leukemia, Chronic, Chronic-Phase" ], "interventions": [ { "name": "Dasatinib in combination with imatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2006-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2016-02-17", "last_synced_at": "2026-10-02T17:35:32.460Z", "location_count": 3, "location_summary": "Los Angeles, California • San Francisco, California • New York, New York", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00324077" }, { "nct_id": "NCT02081378", "title": "A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Myelogenous Leukemia", "Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Asciminib (ABL001)", "type": "DRUG" }, { "name": "Nilotinib", "type": "DRUG" }, { "name": "Imatinib", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 326, "start_date": "2014-04-24", "completion_date": "2023-03-14", "has_results": false, "last_update_posted_date": "2024-03-18", "last_synced_at": "2026-10-02T17:35:32.460Z", "location_count": 6, "location_summary": "Boston, Massachusetts • Ann Arbor, Michigan • New York, New York + 3 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Portland", "state": "Oregon" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02081378" }, { "nct_id": "NCT04877522", "title": "Asciminib Roll-over Study", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Chronic Myelogenous Leukemia", "Leukemia, Myelogenous, Chronic, BCR-ABL Positive" ], "interventions": [ { "name": "Asciminib single agent", "type": "DRUG" }, { "name": "Imatinib", "type": "DRUG" }, { "name": "Nilotinib", "type": "DRUG" }, { "name": "Bosutinib", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Asciminib single agent pediatric formulation", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "7 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "7 Years to 100 Years" }, "enrollment_count": 347, "start_date": "2022-08-30", "completion_date": "2030-08-30", "has_results": false, "last_update_posted_date": "2026-07-06", "last_synced_at": "2026-10-02T17:35:32.460Z", "location_count": 6, "location_summary": "Ann Arbor, Michigan • New York, New York • Portland, Oregon + 3 more", "locations": [ { "city": "Ann Arbor", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Portland", "state": "Oregon" }, { "city": "Dallas", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04877522" }, { "nct_id": "NCT04006847", "title": "Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Myeloid Leukemia, Chronic Phase" ], "interventions": [ { "name": "Eicosapentaenoic Acid", "type": "DRUG" }, { "name": "Tyrosine kinase inhibitor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Milton S. Hershey Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2020-09-14", "completion_date": "2021-05-21", "has_results": true, "last_update_posted_date": "2022-07-01", "last_synced_at": "2026-10-02T17:35:32.460Z", "location_count": 1, "location_summary": "Hershey, Pennsylvania", "locations": [ { "city": "Hershey", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04006847" }, { "nct_id": "NCT03878524", "title": "Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Anatomic Stage IV Breast Cancer AJCC v8", "Anemia", "Ann Arbor Stage III Hodgkin Lymphoma", "Ann Arbor Stage III Non-Hodgkin Lymphoma", "Ann Arbor Stage IV Hodgkin Lymphoma", "Ann Arbor Stage IV Non-Hodgkin Lymphoma", "Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative", "Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Castration-Resistant Prostate Carcinoma", "Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Hematopoietic and Lymphoid System Neoplasm", "Locally Advanced Pancreatic Adenocarcinoma", "Metastatic Breast Carcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Pancreatic Adenocarcinoma", "Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis", "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable", "Primary Myelofibrosis", "Recurrent Acute Lymphoblastic Leukemia", "Recurrent Acute Myeloid Leukemia", "Recurrent Chronic Lymphocytic Leukemia", "Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Recurrent Hematologic Malignancy", "Recurrent Hodgkin Lymphoma", "Recurrent Myelodysplastic Syndrome", "Recurrent Myelodysplastic/Myeloproliferative Neoplasm", "Recurrent Myeloproliferative Neoplasm", "Recurrent Non-Hodgkin Lymphoma", "Recurrent Plasma Cell Myeloma", "Recurrent Small Lymphocytic Lymphoma", "Refractory Acute Lymphoblastic Leukemia", "Refractory Acute Myeloid Leukemia", "Refractory Chronic Lymphocytic Leukemia", "Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Refractory Chronic Myelomonocytic Leukemia", "Refractory Hematologic Malignancy", "Refractory Hodgkin Lymphoma", "Refractory Malignant Solid Neoplasm", "Refractory Myelodysplastic Syndrome", "Refractory Myelodysplastic/Myeloproliferative Neoplasm", "Refractory Non-Hodgkin Lymphoma", "Refractory Plasma Cell Myeloma", "Refractory Primary Myelofibrosis", "Refractory Small Lymphocytic Lymphoma", "Stage II Pancreatic Cancer AJCC v8", "Stage III Pancreatic Cancer AJCC v8", "Stage IV Pancreatic Cancer AJCC v8", "Stage IV Prostate Cancer AJCC v8", "Unresectable Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "Afatinib", "type": "DRUG" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Bicalutamide", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Cabazitaxel", "type": "DRUG" }, { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Celecoxib", "type": "DRUG" }, { "name": "Cobimetinib", "type": "DRUG" }, { "name": "Copanlisib", "type": "DRUG" }, { "name": "Dabrafenib", "type": "DRUG" }, { "name": "Dacomitinib", "type": "DRUG" }, { "name": "Darolutamide", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Enasidenib", "type": "DRUG" }, { "name": "Entrectinib", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Erlotinib", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Idelalisib", "type": "DRUG" }, { "name": "Imatinib", "type": "DRUG" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Lorlatinib", "type": "DRUG" }, { "name": "Losartan", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Neratinib", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Panobinostat", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Pertuzumab", "type": "BIOLOGICAL" }, { "name": "Ponatinib", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Regorafenib", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" }, { "name": "Sunitinib", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" }, { "name": "Trastuzumab Emtansine", "type": "BIOLOGICAL" }, { "name": "Tretinoin", "type": "DRUG" }, { "name": "Vemurafenib", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Vismodegib", "type": "DRUG" }, { "name": "Vorinostat", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE", "OTHER" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 2, "start_date": "2020-04-01", "completion_date": "2020-12-10", "has_results": false, "last_update_posted_date": "2024-03-04", "last_synced_at": "2026-10-02T17:35:32.460Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT03878524" }, { "nct_id": "NCT02551718", "title": "High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Recurrent Acute Leukemia of Ambiguous Lineage", "Recurrent Acute Lymphoblastic Leukemia", "Recurrent Acute Myeloid Leukemia", "Refractory Acute Lymphoblastic Leukemia", "Refractory Acute Myeloid Leukemia", "Refractory Acute Leukemia of Ambiguous Lineage" ], "interventions": [ { "name": "Chemosensitivity Assay", "type": "OTHER" }, { "name": "Cytology Specimen Collection Procedure", "type": "OTHER" }, { "name": "Gene Expression Analysis", "type": "GENETIC" }, { "name": "Genetic Variation Analysis", "type": "GENETIC" }, { "name": "In Vitro Sensitivity-Directed Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "OTHER", "GENETIC", "DRUG" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": null, "sex": "ALL", "summary": "3 Years and older" }, "enrollment_count": 34, "start_date": "2015-09-11", "completion_date": "2021-05-13", "has_results": true, "last_update_posted_date": "2022-06-30", "last_synced_at": "2026-10-02T17:35:32.460Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02551718" }, { "nct_id": "NCT03654768", "title": "Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive" ], "interventions": [ { "name": "Bosutinib", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nilotinib", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Imatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 81, "start_date": "2018-10-24", "completion_date": "2028-07-01", "has_results": true, "last_update_posted_date": "2025-12-18", "last_synced_at": "2026-10-02T17:35:32.460Z", "location_count": 541, "location_summary": "Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 320 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03654768" } ] }